Wikibooks

Radiation Oncology/Liver/Liver Mets

< Radiation Oncology | Liver
This page may need to be reviewed for quality.

Overview

edit
  • Liver is the second most frequently metastatic organ, after lymph nodes
    • Rich dual vascular supply and cell-promoting humoral factors
  • In US/Europe, liver mets are much more frequent than primary liver tumors
  • Primaries most commonly going to liver:
    • Adults: the eye, colon, stomach, pancreas, breast, and lung
    • Children: neuroblastoma, Wilms tumor, and leukemia
  • Seeding: 77% both lobes, 10% single lesions. Multiple mets often vary in size, suggesting seeding from primary in waves
  • Imaging: With an equivalent specificity, PET is the most sensitive (vs. U/S, CT, MRI)
  • Treatment options:
    • Surgery
    • Transcatheter arterial chemoembolization (TACE)
    • Ablation (Cryoablation, Microwave ablation, EtOH ablation, RF ablation, Laser ablation
    • RT historically not used due to low median liver tolerance, but now increasing interest with conformal therapy and stereotactic radiotherapy
  • Survival:
    • Colorectal primary: resection can offer cure, 5-year survival 20-40%
    • Breast, lung, pancreas primary: poor due to usually widespread metastatic disease outside of liver


Treatment

edit

Most studies include both mets and primary liver cancer; for now they are kept together.

Please see the Liver/Treatment page.


Surgery

edit
  • MSKCC; 2007 (1985-1994) PMID 17925551 -- "Actual 10-year survival after resection of colorectal liver metastases defines cure." (Tomlinson JS, J Clin Oncol. 2007 Oct 10;25(29):4575-80.)
    • Retrospective. 612 consecutive patients, 102 10-year survivors
    • Outcome: If survive 10 years, 97% DSS; if survive 5 years, 66% DSS
    • Initial factors: 50% N+, 39% >1 met, 35% tumor size >5cm, 25% bilobar mets, 7% synchronous disease
    • Conclusion: Almost 20% cure in well-selected patients with CRC liver mets
Retrieved from "https://en.wikibooks.org/wiki/Radiation_Oncology/Liver/Liver_Mets"